NCT04551534View on ClinicalTrials.gov

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL201 in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

122

Participants

Timeline

Start Date

June 1, 2017

Primary Completion Date

August 8, 2018

Study Completion Date

August 8, 2018

Conditions
Healthy Volunteers
Interventions
DRUG

DNL201

Oral dose(s)

DRUG

Placebo

Oral dose(s)

Trial Locations (1)

05247

Clinical Site(s), Dallas

Sponsors
All Listed Sponsors
lead

Denali Therapeutics Inc.

INDUSTRY